(Q44943067)

7 December 2017

title

Alendronate in the prevention of osteoporosis: 7-year follow-up (English)

1 reference

7 December 2017

0 references

P N Sambrook

1

1 reference

7 December 2017

J P Rodriguez

2

1 reference

7 December 2017

R D Wasnich

3

1 reference

7 December 2017

M M Luckey

4

1 reference

7 December 2017

A Kaur

5

1 reference

7 December 2017

L Meng

6

1 reference

7 December 2017

A Lombardi

7

1 reference

7 December 2017

language of work or name

English

0 references

publication date

13 February 2004

1 reference

Osteoporosis International

7 December 2017

published in

1 reference

7 December 2017

volume

15

1 reference

7 December 2017

issue

6

1 reference

7 December 2017

page(s)

483-488

1 reference

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

7 December 2017

cites work

1 reference

12 December 2020

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

1 reference

12 December 2020

Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers

1 reference

12 December 2020

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

1 reference

12 December 2020

Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women

1 reference

12 December 2020

Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups

1 reference

12 December 2020

Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

1 reference

12 December 2020

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

12 December 2020

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

1 reference

12 December 2020

Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial

1 reference

12 December 2020

Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group

1 reference

12 December 2020

Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group

1 reference

12 December 2020

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

12 December 2020

The prevention and treatment of osteoporosis

1 reference

12 December 2020

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

10.1007/S00198-003-1571-4

Identifiers

DOI

1 reference

7 December 2017

1 reference